Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4% - Should You Sell?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report)'s share price fell 4% during mid-day trading on Monday . The stock traded as low as $11.30 and last traded at $11.61. 19,728 shares were traded during trading, a decline of 35% from the average session volume of 30,376 shares. The stock had previously closed at $12.10.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Greenwich LifeSciences Price Performance

The company has a market capitalization of $152.61 million, a price-to-earnings ratio of -14.51 and a beta of 1.69. The stock has a 50 day moving average price of $12.42 and a two-hundred day moving average price of $13.24.

Insider Activity at Greenwich LifeSciences

In related news, CEO Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock in a transaction on Friday, January 10th. The shares were purchased at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the acquisition, the chief executive officer now owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. This represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought a total of 9,500 shares of company stock worth $115,549 over the last 90 days. Insiders own 51.67% of the company's stock.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after buying an additional 5,861 shares during the last quarter. Northern Trust Corp raised its position in Greenwich LifeSciences by 17.3% in the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company's stock valued at $982,000 after buying an additional 12,923 shares during the last quarter. State Street Corp raised its position in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company's stock valued at $1,026,000 after buying an additional 3,005 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Finally, Barclays PLC raised its position in Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after buying an additional 1,088 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads